Dexcom (DXCM) Net Income towards Common Stockholders Growth (1y) (2011 - 2026)
Dexcom (DXCM) Net Income towards Common Stockholders Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 200.50 Bn | 194.89 Bn | 7.27 Bn | -47.84% |
| 2 | Stryker | 130.00 Bn | 126.52 Bn | 4.50 Bn | 44.34% |
| 3 | Medtronic | 120.36 Bn | 111.14 Bn | 6.41 Bn | 18.55% |
| 4 | Boston Scientific | 74.19 Bn | 73.65 Bn | 3.85 Bn | 13.80% |
| 5 | Edwards Lifesciences | 52.73 Bn | 48.48 Bn | 1.35 Bn | -27.18% |
| 6 | Dexcom | 34.64 Bn | 32.70 Bn | 830.00 Mn | 38.54% |
| 7 | GE HealthCare Technologies | 34.13 Bn | 32.02 Bn | 2.18 Bn | 14.80% |
| 8 | Koninklijke Philips | 26.52 Bn | 23.20 Bn | 4.55 Bn | 73.85% |
| 9 | Steris | 23.23 Bn | 22.75 Bn | 684.20 Mn | 12.92% |
| 10 | Zimmer Biomet Holdings | 19.39 Bn | 18.98 Bn | 1.54 Bn | 30.12% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 38.54% |
| Mar 31, 2026 | 89.28% |
| Dec 31, 2025 | 76.20% |
| Sep 30, 2025 | 110.85% |
| Jun 30, 2025 | 25.30% |
| Mar 31, 2025 | -28.01% |
| Dec 31, 2024 | -40.81% |
| Sep 30, 2024 | 11.52% |
| Jun 30, 2024 | 23.81% |
| Mar 31, 2024 | 201.23% |
| Dec 31, 2023 | 179.19% |
| Sep 30, 2023 | 19.27% |
| Jun 30, 2023 | 127.70% |
| Mar 31, 2023 | -50.05% |
| Dec 31, 2022 | 1,832.08% |
| Sep 30, 2022 | 15.92% |
| Jun 30, 2022 | -35.08% |
| Mar 31, 2022 | 72.21% |
| Dec 31, 2021 | -101.29% |
| Sep 30, 2021 | 20.91% |